Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody - PubMed (original) (raw)

Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody

D D Ho et al. Proc Natl Acad Sci U S A. 1991.

Abstract

To define the domains in the envelope glycoprotein important for antibody neutralization of the human immunodeficiency virus type 1 (HIV-1), monoclonal antibodies (mAbs) were generated by immunizing mice with purified glycoprotein gp120 of the IIIB isolate. One mAb, G3-4, reacted with the gp120 of homologous (IIIB) and heterologous (RF) isolates. In addition, mAb G3-4 efficiently neutralized both IIIB and RF viruses in vitro, as well as four of nine primary HIV-1 isolates. In competition immunoassays, mAb G3-4 and soluble CD4 were found to inhibit one another in binding to gp120. However, no competition was seen between mAb G3-4 and mAbs directed to the third variable region or the fourth conserved region of gp120. In particular, mAb G3-4 did not compete with our human mAb 15e, which identifies a discontinuous epitope on gp120 involved in group-specific neutralization of HIV-1 and in gp120-CD4 binding. Epitope-mapping studies on mAb G3-4 with synthetic or unglycosylated recombinant peptides were negative, suggesting that its epitope may be discontinuous. Indeed, this hypothesis was confirmed by showing the loss of mAb G3-4 serologic reactivity when gp120 was first denatured. We conclude that the site recognized by mAb G3-4 represents another discontinuous epitope on gp120 important for neutralization of HIV-1.

PubMed Disclaimer

Cited by

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.
Sattentau QJ, Moore JP. Sattentau QJ, et al. J Exp Med. 1995 Jul 1;182(1):185-96. doi: 10.1084/jem.182.1.185. J Exp Med. 1995. PMID: 7540648 Free PMC article.
Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.
Gorny MK, Stamatatos L, Volsky B, Revesz K, Williams C, Wang XH, Cohen S, Staudinger R, Zolla-Pazner S. Gorny MK, et al. J Virol. 2005 Apr;79(8):5232-7. doi: 10.1128/JVI.79.8.5232-5237.2005. J Virol. 2005. PMID: 15795308 Free PMC article.
The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
Pinter A, Honnen WJ, D'Agostino P, Gorny MK, Zolla-Pazner S, Kayman SC. Pinter A, et al. J Virol. 2005 Jun;79(11):6909-17. doi: 10.1128/JVI.79.11.6909-6917.2005. J Virol. 2005. PMID: 15890930 Free PMC article.

References

1. J Immunol. 1990 Oct 1;145(7):2199-206 - PubMed
1. AIDS. 1990 Apr;4(4):297-305 - PubMed
1. Science. 1984 May 4;224(4648):497-500 - PubMed
1. J Virol. 1991 Jan;65(1):489-93 - PubMed
1. J Virol. 1990 Dec;64(12):5701-7 - PubMed

Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody - PubMed (original) (raw)